マーケットレポート詳細
モノクローナル抗体医薬品市場：2029年に至る製造法別、治療分野別予測
Monoclonal Antibody (mABs) Therapeutics Market by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Global Forecast to 2029
- 出版元：MarketsandMarkets
出版元について - 発行年：2024年3月
- 定価 ：Single User License(1名様ライセンス)US$4,950(米国ドル)/ Multi User License(5名様)$6,650 / Corporate User License $8,150
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文351ページになります。
- 商品コード：MAM3569
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
モノクローナル抗体医薬品の世界市場規模は2024年で2526億ドル、2029年に4975億ドル、市場の平均年成長率は14.5%にて増加すると見込まれています。
レポートはモノクローナル抗体の世界市場について2029年までの市場予測データ(金額US$)を掲載しています。同市場をさまざまな区分で細分化し、そのセグメント市場ごとの市場予測（製造方法別、市場、投与経路別市場、等）を中心に構成されています。また競合状況、主要企業情報（15社）、バリューチェーン分析、特許分析なども加味し、モノクローナル抗体医薬品市場の動向および今後成長性を詳細にレポートしています。
【レポート構成概要】
◆モノクローナル抗体医薬品市場の世界市場予測2022-2029年
・市場規模(US$)
◆製造方法別、市場-2029年
・試験管内生産 (In Vitro)
・生体内生産 (In Vivo)
※(市場規模US$)
◆投与経路別、市場-2029年
・静脈内投与
・皮下投与経路
・その他投与経路
※(市場規模US$)
◆由来原料別、市場-2029年
・ヒューマンソース
・ヒューマナイズドソース
・キメラソース
・その他由来原料
※(市場規模US$)
◆治療エリア別、市場-2029年
・炎症性/自己免疫疾患
・腫瘍
・血液内科
・眼科
・その他治療エリア
※(市場規模US$)
◆エンドユーザー別、市場-2029年
・病院
・長期療養施設
・その他エンドユーザー
※(市場規模US$)
◆主要国地域別市場-2029年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン、トルコ
・その他欧州
アジア太平洋
・日本、中国、インド
・韓国、インドネシア、マレーシア
・その他アジア太平洋
中南米
・ブラジル
・その他中南米
中東
・GCC諸国
-サウジアラビア
-アラブ首長国連邦
-その他GCC諸国
・その他中東
アフリカ
※地域、国別に、全セグメント別の細分化データ掲載、詳細は目次参照
◆市場分析
・市場ダイナミクス
・ファイブフォース分析
・技術分析
・バリューチェーン分析
・特許分析
・サプライチェーン分析
・エコシステム分析
・規制状況
・平均価格分析
・主要なステークホルダーと購買基準
・競合状況
・市場シェア分析
◆モノクローナル抗体医薬品市場の主要企業プロフィール動向
・F HOFFMANN-LA ROCHE LTD
・JOHNSON & JOHNSON SERVICES, INC
・MERCK & CO, INC
・ABBVIE INC
・BRISTOL-MYERS SQUIBB COMPANY
・ASTRAZENECA
・SANOFI
・NOVARTIS AG
・AMGEN INC
・武田薬品工業株式会社
・GSK PLC
・ELI LILLY AND COMPANY
・REGENERON PHARMACEUTICALS INC
・BIOGEN
・UCB SA
その他企業
・BOEHRINGER INGELHEIM INTERNATIONAL GMBH
・Y-MABS THERAPEUTICS, INC
・TEVA PHARMACEUTICAL INDUSTRIES LTD
・MERCK KGAA
・協和キリン株式会社
・SWEDISH ORPHAN BIOVITRUM AB
・UNITED THERAPEUTICS CORPORATION
・THERATECHNOLOGIES INC
・INCYTE
・SUN PHARMACEUTICAL INDUSTRIES, INC
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS 29
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 RESEARCH LIMITATIONS
1.5 STAKEHOLDERS
1.6 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
・ FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
・ FIGURE 2 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
・ FIGURE 3 MONOCLONAL ANTIBODY THERAPEUTICS: MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2023
・ FIGURE 4 MONOCLONAL ANTIBODY THERAPEUTICS: MARKET SIZE ESTIMATION (PRODUCT-BASED ANALYSIS), 2023
・ FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023
・ FIGURE 6 ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE AG: REVENUE SHARE ANALYSIS, 2023
2.2.1 INSIGHTS FROM PRIMARIES
・ FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
2.2.2 SEGMENT ASSESSMENT (BY PRODUCTION METHOD, SOURCE, ROUTE OF ADMINISTRATION, THERAPY AREA, AND END USER)
・ FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3 GROWTH RATE ASSUMPTIONS
・ FIGURE 9 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: CAGR PROJECTIONS, 2024–2029
・ FIGURE 10 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
・ FIGURE 11 DATA TRIANGULATION METHODOLOGY
2.5 STUDY ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
・ FIGURE 12 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2024 VS. 2029 (USD MILLION)
・ FIGURE 13 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD MILLION)
・ FIGURE 14 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY TYPE, 2024 VS. 2029 (USD MILLION)
・ FIGURE 15 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
・ FIGURE 16 GEOGRAPHICAL SNAPSHOT OF MONOCLONAL ANTIBODY THERAPEUTICS MARKET
4 PREMIUM INSIGHTS
4.1 MONOCLONAL ANTIBODY THERAPEUTICS MARKET OVERVIEW
・ FIGURE 17 ADVANCEMENTS IN BIOTECHNOLOGY AND GENETIC ENGINEERING TO DRIVE MARKET DURING FORECAST PERIOD
4.2 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD (2023)
・ FIGURE 18 IN-VITRO PRODUCTION METHOD ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
4.3 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2024 VS. 2029 (USD MILLION)
・ FIGURE 19 HUMAN SOURCE SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
4.4 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
・ FIGURE 20 GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
・ FIGURE 21 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 ADVANCEMENTS IN BIOTECHNOLOGY AND GENETIC ENGINEERING
5.2.1.2 INCREASING DEMAND FOR PERSONALIZED MEDICINE
5.2.1.3 GROWING PRODUCT PIPELINE OF MAB THERAPEUTICS
・ FIGURE 22 NUMBER OF ANTIBODY THERAPEUTICS GRANTED FIRST APPROVAL IN US/EU (2012−2023)
5.2.2 RESTRAINTS
5.2.2.1 STRINGENT REGULATORY APPROVAL PROCESS
5.2.2.2 HIGH COST OF MAB TREATMENTS
5.2.3 OPPORTUNITIES
5.2.3.1 INNOVATIVE THERAPEUTIC INDICATIONS
5.2.3.2 RISING TECHNOLOGICAL ADVANCEMENTS IN ANTIBODY ENGINEERING
5.2.4 CHALLENGES
5.2.4.1 RISING DEVELOPMENT & PRODUCTION COSTS
5.3 PORTER’S FIVE FORCES ANALYSIS
・ TABLE 1 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT OF NEW ENTRANTS
5.3.2 THREAT OF SUBSTITUTES
5.3.3 BARGAINING POWER OF SUPPLIERS
5.3.4 BARGAINING POWER OF BUYERS 60
5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 TECHNOLOGY ANALYSIS
5.4.1 CONVENTIONAL PRODUCTION OF MABS
5.4.2 TECHNOLOGICAL ADVANCEMENTS FOR MABS
・ TABLE 2 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: TECHNOLOGY COMPARISON
5.5 VALUE CHAIN ANALYSIS
・ FIGURE 23 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: VALUE CHAIN
5.6 PATENT ANALYSIS
5.6.1 METHODOLOGY
5.6.2 PATENTS FILED BY DOCUMENT TYPE, 2014–2023
・ TABLE 3 PATENTS FILED, 2014–2023
5.6.3 INNOVATION AND PATENT APPLICATIONS
・ FIGURE 24 TOTAL NUMBER OF PATENTS GRANTED, 2014–2023
5.6.4 TOP APPLICANTS
・ FIGURE 25 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014–2023
・ FIGURE 26 REGIONAL ANALYSIS OF PATENTS GRANTED, 2014–2023
・ TABLE 4 TOP 10 PATENT OWNERS IN MONOCLONAL ANTIBODY THERAPEUTICS MARKET, 2013–2023
・ TABLE 5 PATENTS IN MONOCLONAL ANTIBODY THERAPEUTICS MARKET, 2023−2024
5.7 KEY CONFERENCES & EVENTS
・ TABLE 6 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2024–2025)
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 PIPELINE ANALYSIS
・ TABLE 7 MONOCLONAL ANTIBODY THERAPEUTICS IN CLINICAL PIPELINE
5.10 SUPPLY CHAIN ANALYSIS
・ FIGURE 27 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS
5.11 ECOSYSTEM ANALYSIS
・ FIGURE 28 MONOCLONAL ANTIBODY THERAPEUTICS ECOSYSTEM
5.11.1 MONOCLONAL ANTIBODY THERAPEUTIC VENDORS
・ TABLE 8 MONOCLONAL ANTIBODY THERAPEUTIC VENDORS
5.11.2 END USERS OF MONOCLONAL ANTIBODY THERAPEUTICS
・ TABLE 9 MONOCLONAL ANTIBODY THERAPEUTIC END USERS
5.11.3 REGULATORY BODIES FOR MONOCLONAL ANTIBODY THERAPEUTICS
・ TABLE 10 MONOCLONAL ANTIBODY THERAPEUTIC REGULATORY BODIES
5.12 REGULATORY LANDSCAPE
5.12.1 REGULATORY ANALYSIS
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・ TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・ TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・ TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
・ TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PRICING ANALYSIS
5.13.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS
・ TABLE 15 AVERAGE SELLING PRICE OF MONOCLONAL ANTIBODY THERAPEUTICS IN US
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
・ FIGURE 29 TECHNOLOGICAL ADVANCEMENTS IN MONOCLONAL ANTIBODY PRODUCTION TO DRIVE MARKET GROWTH
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS ON BUYING PROCESS
・ FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MABS AMONG TOP TWO END USERS
・ TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP TWO END USERS
5.15.2 BUYING CRITERIA FOR MONOCLONAL ANTIBODY THERAPEUTICS
・ FIGURE 31 KEY BUYING CRITERIA FOR HOSPITALS AND LONG-TERM CARE FACILITIES
・ TABLE 17 KEY BUYING CRITERIA FOR TOP TWO END USERS
6 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD
6.1 INTRODUCTION
・ TABLE 18 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
6.2 IN-VITRO PRODUCTION
6.2.1 HIGH SCALABILITY AND COST EFFICIENCY TO PROPEL MARKET
・ TABLE 19 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 20 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 21 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 22 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 23 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 24 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 25 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
6.3 IN-VIVO PRODUCTION
6.3.1 MINIMAL SIDE-EFFECTS TO SUPPORT MARKET GROWTH
・ TABLE 26 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 27 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 28 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 29 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 30 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 31 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 32 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION)
7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
7.1 INTRODUCTION
・ TABLE 33 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
7.2 INTRAVENOUS ROUTE OF ADMINISTRATION
7.2.1 DIRECT DELIVERY OF THERAPEUTIC DOSAGE FOR MULTIPLE INDICATIONS TO DRIVE MARKET
・ TABLE 34 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 35 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 36 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 37 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 38 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 39 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 40 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
7.3 SUBCUTANEOUS ROUTE OF ADMINISTRATION
7.3.1 ENHANCED PATIENT ADHERENCE AND LOW HEALTHCARE COSTS TO DRIVE MARKET
・ TABLE 41 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 42 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 43 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 44 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 45 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 46 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022−2029 USD MILLION)
・ TABLE 47 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
7.4 OTHER ROUTES OF ADMINISTRATION
・ TABLE 48 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 49 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 50 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 51 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 52 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 53 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 54 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTESC OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION)
8 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE
8.1 INTRODUCTION
・ TABLE 55 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
8.2 HUMAN SOURCE
8.2.1 REDUCED IMMUNOGENICITY AND IMPROVED EFFICACY TO PROPEL MARKET
・ TABLE 56 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 57 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 58 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 59 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 60 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 61 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 62 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
8.3 HUMANIZED SOURCE
8.3.1 ABILITY TO ADJUST SPECIFICITY AND BIOLOGICAL FUNCTIONS TO DRIVE MARKET
・ TABLE 63 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 64 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 65 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 66 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 67 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 68 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 69 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
8.4 CHIMERIC SOURCE
8.4.1 UTILIZATION OF GENETIC ENGINEERING TECHNIQUES FOR MINIMIZED IMMUNOGENIC RESPONSES TO FUEL MARKET
・ TABLE 70 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 71 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 72 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 73 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 74 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 75 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 76 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION)
8.5 OTHER SOURCES
・ TABLE 77 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 78 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 79 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 80 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 81 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 82 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 83 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION)
9 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA
9.1 INTRODUCTION
・ TABLE 84 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
9.2 INFLAMMATORY & AUTOIMMUNE DISORDERS
9.2.1 RISING DEMAND FOR TARGETED THERAPEUTICS TO DRIVE MARKET
・ TABLE 85 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 86 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 87 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 88 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 89 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 90 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 91 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
9.3 ONCOLOGY
9.3.1 GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO PROPEL MARKET
・ TABLE 92 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 93 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 94 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 95 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 96 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 97 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY REGION, 2022−2029 (USD MILLION)
・ TABLE 98 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022−2029 (USD MILLION)
9.4 HEMATOLOGY
9.4.1 RISING INCIDENCE OF THROMBOTIC DISORDERS TO SUPPORT MARKET GROWTH
・ TABLE 99 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY REGION, 2022−2029 (USD MILLION)
・ TABLE 100 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 101 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022−2029 (USD MILLION)
・ TABLE 102 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 103 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 104 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 105 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
9.5 OPHTHALMOLOGY
9.5.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION TO BOOST DEMAND
・ TABLE 106 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 107 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 108 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 109 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 110 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 111 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 112 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
9.6 OTHER THERAPY AREAS
・ TABLE 113 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 114 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 115 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 116 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 117 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 118 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 119 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
10 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER
10.1 INTRODUCTION
・ TABLE 120 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
10.2 HOSPITALS
10.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET
・ TABLE 121 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 122 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 123 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 124 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 125 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 126 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 127 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
10.3 LONG-TERM CARE FACILITIES
10.3.1 SPECIALIZED CARE AND CONTINUOUS MONITORING ADVANTAGES TO DRIVE MARKET
・ TABLE 128 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 129 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 130 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 131 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 132 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 133 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 134 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION)
10.4 OTHER END USERS
・ TABLE 135 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 136 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 137 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 138 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 139 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 140 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 141 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
11 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY REGION
11.1 INTRODUCTION
・ TABLE 142 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
11.2 NORTH AMERICA
・ FIGURE 32 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET SNAPSHOT
・ TABLE 143 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 144 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 145 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 146 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 147 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 148 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.2.1 NORTH AMERICA: RECESSION IMPACT
11.2.2 US
11.2.2.1 RISING REGULATORY APPROVALS FOR PRODUCT COMMERCIALIZATION TO PROPEL MARKET
・ TABLE 149 PRODUCT APPROVALS FOR MAB THERAPEUTICS BY US FDA
・ TABLE 150 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 151 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 152 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 153 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 154 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.2.3 CANADA
11.2.3.1 RISING INVESTMENTS IN ANTIBODY RESEARCH TO SUPPORT MARKET GROWTH
・ TABLE 155 CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 156 CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 157 CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 158 CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 159 CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3 EUROPE
・ FIGURE 33 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET SNAPSHOT
・ TABLE 160 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 161 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 162 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 163 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 164 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 165 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.1 EUROPE: RECESSION IMPACT
11.3.2 GERMANY
11.3.2.1 RISING NUMBER OF CLINICAL TRIALS FOR MAB THERAPEUTICS TO DRIVE MARKET
・ TABLE 166 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 167 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 168 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 169 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 170 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.3 UK
11.3.3.1 INCREASING R&D INITIATIVES BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO SUPPORT MARKET GROWTH
・ TABLE 171 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
・ TABLE 172 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 173 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 174 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 175 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 176 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 FAVORABLE REIMBURSEMENT POLICIES FOR THERAPEUTIC TREATMENTS TO PROPEL MARKET
・ TABLE 177 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 178 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 179 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 180 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 181 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.5 ITALY
11.3.5.1 GROWTH IN LIFE SCIENCES INDUSTRY TO BOOST DEMAND
・ TABLE 182 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 183 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 184 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 185 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 186 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 GROWING FOCUS ON RESEARCH FOR BIOMATERIAL DEVELOPMENT TO DRIVE MARKET
・ TABLE 187 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 188 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 189 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 190 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 191 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.7 TURKEY
11.3.7.1 RISING INVESTMENTS IN R&D FOR HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
・ TABLE 192 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 193 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 194 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 195 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 196 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.8 REST OF EUROPE
・ TABLE 197 REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 198 REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 199 REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 200 REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 201 REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4 ASIA PACIFIC
・ TABLE 202 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 203 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 204 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 205 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 206 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 207 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.1 ASIA PACIFIC: RECESSION IMPACT
11.4.2 CHINA
11.4.2.1 GROWING PREFERENCE FOR PRECISION MEDICINES TO PROPEL MARKET
・ TABLE 208 CHINA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 209 CHINA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 210 CHINA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 211 CHINA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 212 CHINA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.3 JAPAN
11.4.3.1 AVAILABILITY OF HEALTHCARE INSURANCE AND FAVORABLE REGULATORY ENVIRONMENT TO PROPEL MARKET
・ TABLE 213 JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 214 JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 215 JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 216 JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 217 JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.4 INDIA
11.4.4.1 INCREASING INCIDENCE OF CHRONIC DISEASES AND HIGH GROWTH IN PHARMA R&D TO FUEL MARKET
・ TABLE 218 INDIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 219 INDIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 220 INDIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 221 INDIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 222 INDIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.5 SOUTH KOREA
11.4.5.1 STRATEGIC INITIATIVES BY KEY PLAYERS TO SUPPORT MARKET GROWTH
・ TABLE 223 SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 224 SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 225 SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 226 SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 227 SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.6 INDONESIA
11.4.6.1 FUNDING INITIATIVES AND KEY PRODUCT LAUNCHES TO SUPPORT MARKET GROWTH
・ TABLE 228 INDONESIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 229 INDONESIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 230 INDONESIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 231 INDONESIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 232 INDONESIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.7 MALAYSIA
11.4.7.1 INCREASING FOCUS ON GOVERNMENT-FUNDED INITIATIVES FOR MANAGEMENT OF CHRONIC AILMENTS TO SUPPORT MARKET GROWTH
・ TABLE 233 MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 234 MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 235 MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 236 MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 237 MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.8 REST OF ASIA PACIFIC
・ TABLE 238 REST OF ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 239 REST OF ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 240 REST OF ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 211
・ TABLE 241 REST OF ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 242 REST OF ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5 LATIN AMERICA
・ TABLE 243 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 244 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 245 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 246 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 247 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 248 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5.1 LATIN AMERICA: RECESSION IMPACT
11.5.2 BRAZIL
11.5.2.1 INCREASING INCIDENCE OF CHRONIC & INFECTIOUS DISEASES TO DRIVE MARKET
・ TABLE 249 BRAZIL: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 250 BRAZIL: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 251 BRAZIL: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 252 BRAZIL: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 253 BRAZIL: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5.3 REST OF LATIN AMERICA
・ TABLE 254 REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 255 REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 256 REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 219
・ TABLE 257 REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 258 REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6 MIDDLE EAST
・ TABLE 259 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
・ TABLE 260 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 261 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 262 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 263 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 264 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6.1 MIDDLE EAST: RECESSION IMPACT
11.6.2 GCC COUNTRIES
・ TABLE 265 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
・ TABLE 266 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 267 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 268 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 269 GCC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 270 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6.2.1 SAUDI ARABIA
11.6.2.1.1 RISING PREVALENCE OF CVD TO SUPPORT MARKET GROWTH
・ TABLE 271 SAUDI ARABIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 272 SAUDI ARABIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 273 SAUDI ARABIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 274 SAUDI ARABIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 275 SAUDI ARABIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6.2.2 UNITED ARAB EMIRATES
11.6.2.2.1 RISING PREVALENCE OF DIABETES TO BOOST DEMAND
・ TABLE 276 UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 277 UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 278 UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 229
・ TABLE 279 UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 280 UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6.2.3 OTHER GCC COUNTRIES
・ TABLE 281 OTHER GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 282 OTHER GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 283 OTHER GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 231
・ TABLE 284 OTHER GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 285 OTHER GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6.3 REST OF MIDDLE EAST
・ TABLE 286 REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 287 REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 288 REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 234
・ TABLE 289 REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION)
・ TABLE 290 REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.7 AFRICA
11.7.1 HIGH INVESTMENTS IN HEALTHCARE R&D TO SUPPORT MARKET GROWTH
・ TABLE 291 AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION)
・ TABLE 292 AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)
・ TABLE 293 AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
・ TABLE 294 AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 237
・ TABLE 295 AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.7.2 AFRICA: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
・ FIGURE 34 STRATEGIES ADOPTED BY KEY PLAYERS IN MONOCLONAL ANTIBODY THERAPEUTICS MARKET
12.3 REVENUE SHARE ANALYSIS
・ FIGURE 35 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2020−2023)
12.4 MARKET SHARE ANALYSIS
・ FIGURE 36 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
・ TABLE 296 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DEGREE OF COMPETITION
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
・ FIGURE 37 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2023)
12.5.5 COMPANY FOOTPRINT
・ FIGURE 38 COMPANY FOOTPRINT (15 COMPANIES)
12.5.5.1 TYPE FOOTPRINT
・ TABLE 297 TYPE FOOTPRINT (15 COMPANIES)
12.5.5.2 REGIONAL FOOTPRINT
・ TABLE 298 REGIONAL FOOTPRINT (15 COMPANIES)
12.6 COMPANY EVALUATION MATRIX: STARTUP/SME PLAYERS
12.6.1 PROGRESSIVE COMPANIES
12.6.2 DYNAMIC COMPANIES
12.6.3 RESPONSIVE COMPANIES
12.6.4 STARTING BLOCKS
・ FIGURE 39 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2023)
12.7 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
・ TABLE 299 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
・ TABLE 300 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
12.8 VALUATION AND FINANCIAL METRICS OF MONOCLONAL ANTIBODY THERAPEUTIC VENDORS
・ FIGURE 40 EV/EBITDA OF KEY VENDORS
・ FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
12.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
12.9.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND SOURCE
・ FIGURE 42 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND SOURCE
12.9.1.1 F. HOFFMANN-LA ROCHE LTD.
12.9.1.2 JOHNSON & JOHNSON SERVICES, INC.
12.9.1.3 MERCK & CO., INC.
12.9.1.4 ABBVIE INC.
12.9.1.5 SANOFI
12.9.2 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND HUMAN SOURCE
・ FIGURE 43 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND HUMAN SOURCE
12.9.2.1 ASTRAZENECA
12.9.2.2 BRISTOL MYERS SQUIBB COMPANY
12.9.2.3 NOVARTIS AG
12.10 COMPETITIVE SCENARIO
12.10.1 PRODUCT LAUNCHES & APPROVALS
・ TABLE 301 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2021−JANUARY 2024)
12.10.2 DEALS
・ TABLE 302 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DEALS (JANUARY 2021−JANUARY 2024)
12.10.3 OTHER DEVELOPMENTS
・ TABLE 303 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: OTHER DEVELOPMENTS (JANUARY 2021−JANUARY 2024)
13 COMPANY PROFILES
(BUSINESS OVERVIEW, PRODUCTS/SERVICES OFFERED, RECENT DEVELOPMENTS & MNM VIEW)*
13.1 KEY PLAYERS
13.1.1 F. HOFFMANN-LA ROCHE LTD.
・ TABLE 304 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
・ FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
・ TABLE 305 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
・ TABLE 306 F. HOFFMAN LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS
・ TABLE 307 F. HOFFMAN LA ROCHE LTD.: DEALS
13.1.2 JOHNSON & JOHNSON SERVICES, INC.
・ TABLE 308 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
・ FIGURE 45 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2022)
・ TABLE 309 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS/SERVICES OFFERED
・ TABLE 310 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT APPROVALS
13.1.3 MERCK & CO., INC.
・ TABLE 311 MERCK & CO., INC.: COMPANY OVERVIEW
・ FIGURE 46 MERCK & CO., INC COMPANY SNAPSHOT (2022)
・ TABLE 312 MERCK & CO., INC.: PRODUCTS/SERVICES OFFERED
・ TABLE 313 MERCK & CO., INC.: PRODUCT APPROVALS
13.1.4 ABBVIE INC.
・ TABLE 314 ABBVIE INC.: COMPANY OVERVIEW
・ FIGURE 47 ABBVIE INC.: COMPANY SNAPSHOT (2022)
・ TABLE 315 ABBVIE INC.: PRODUCTS /SERVICES OFFERED
・ TABLE 316 ABBVIE INC.: PRODUCT APPROVALS 280
・ TABLE 317 ABBVIE INC.: DEALS
13.1.5 BRISTOL-MYERS SQUIBB COMPANY 282
・ TABLE 318 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
・ FIGURE 48 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2022)
・ TABLE 319 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS/SERVICES OFFERED
・ TABLE 320 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS
・ TABLE 321 BRISTOL-MYERS SQUIBB COMPANY: DEALS
・ TABLE 322 BRISTOL-MYERS SQUIBB COMPANY: OTHER DEVELOPMENTS
13.1.6 ASTRAZENECA
・ TABLE 323 ASTRAZENECA: COMPANY OVERVIEW
・ FIGURE 49 ASTRAZENECA: COMPANY SNAPSHOT (2022)
・ TABLE 324 ASTRAZENECA: PRODUCTS/SERVICES OFFERED
・ TABLE 325 ASTRAZENECA: PRODUCT APPROVALS 290
・ TABLE 326 ASTRAZENECA: DEALS
13.1.7 SANOFI
・ TABLE 327 SANOFI: COMPANY OVERVIEW
・ FIGURE 50 SANOFI: COMPANY SNAPSHOT (2022)
・ TABLE 328 SANOFI: PRODUCTS/SERVICES OFFERED
・ TABLE 329 SANOFI: PRODUCT APPROVALS
・ TABLE 330 SANOFI: DEALS
13.1.8 NOVARTIS AG
・ TABLE 331 NOVARTIS AG: COMPANY OVERVIEW
・ FIGURE 51 NOVARTIS AG: COMPANY SNAPSHOT (2022)
・ TABLE 332 NOVARTIS AG: PRODUCTS/SERVICES OFFERED
・ TABLE 333 NOVARTIS AG: PRODUCT APPROVALS
・ TABLE 334 NOVARTIS AG: DEALS
・ TABLE 335 NOVARTIS AG: OTHER DEVELOPMENTS
13.1.9 AMGEN INC.
・ TABLE 336 AMGEN INC.: COMPANY OVERVIEW 304
・ FIGURE 52 AMGEN INC.: COMPANY SNAPSHOT (2022)
・ TABLE 337 AMGEN INC.: PRODUCTS/SERVICES OFFERED
・ TABLE 338 AMGEN INC.: PRODUCT APPROVALS
・ TABLE 339 AMGEN INC.: DEALS
・ TABLE 340 AMGEN INC.: EXPANSIONS
13.1.10 TAKEDA PHARMACEUTICAL COMPANY LIMITED
・ TABLE 341 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
・ FIGURE 53 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)
・ TABLE 342 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS/SERVICES OFFERED
・ TABLE 343 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS
13.1.11 GSK PLC.
・ TABLE 344 GSK PLC.: COMPANY OVERVIEW 312
・ FIGURE 54 GSK PLC.: COMPANY SNAPSHOT (2022)
・ TABLE 345 GSK PLC.: PRODUCTS/SERVICES OFFERED
・ TABLE 346 GSK PLC.: PRODUCT APPROVALS 314
・ TABLE 347 GSK PLC.: DEALS
・ TABLE 348 GSK PLC.: OTHER DEVELOPMENTS 316
13.1.12 ELI LILLY AND COMPANY
・ TABLE 349 ELI LILLY AND COMPANY: COMPANY OVERVIEW
・ FIGURE 55 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022)
・ TABLE 350 ELI LILLY AND COMPANY: PRODUCTS/SERVICES OFFERED
・ TABLE 351 ELI LILLY AND COMPANY: PRODUCT APPROVALS
・ TABLE 352 ELI LILLY AND COMPANY: DEALS 320
・ TABLE 353 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS
13.1.13 REGENERON PHARMACEUTICALS INC.
・ TABLE 354 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW
・ FIGURE 56 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2022)
・ TABLE 355 REGENERON PHARMACEUTICALS INC.: PRODUCTS/SERVICES OFFERED
・ TABLE 356 REGENERON PHARMACEUTICALS INC.: PRODUCT APPROVALS
・ TABLE 357 REGENERON PHARMACEUTICALS INC.: DEALS
13.1.14 BIOGEN
・ TABLE 358 BIOGEN: COMPANY OVERVIEW
・ FIGURE 57 BIOGEN: COMPANY SNAPSHOT (2022)
・ TABLE 359 BIOGEN: PRODUCTS/SERVICES OFFERED
・ TABLE 360 BIOGEN: PRODUCT APPROVALS
・ TABLE 361 BIOGEN: DEALS
13.1.15 UCB S.A.
・ TABLE 362 UCB S.A.: COMPANY OVERVIEW
・ FIGURE 58 UCB S.A.: COMPANY SNAPSHOT (2022)
・ TABLE 363 UCB S.A.: PRODUCTS/SERVICES OFFERED
・ TABLE 364 UCB S.A.: DEALS
・ TABLE 365 UCB S.A.: PRODUCT APPROVALS 333
13.2 OTHER PLAYERS
13.2.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
13.2.2 Y-MABS THERAPEUTICS, INC.
13.2.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.2.4 MERCK KGAA
13.2.5 KYOWA KIRIN CO., LTD.
13.2.6 SWEDISH ORPHAN BIOVITRUM AB 339
13.2.7 UNITED THERAPEUTICS CORPORATION
13.2.8 THERATECHNOLOGIES INC.
13.2.9 INCYTE
13.2.10 SUN PHARMACEUTICAL INDUSTRIES, INC.
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS/SERVICES OFFERED, RECENT DEVELOPMENTS & MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.